Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001104659-25-014386
Filing Date
2025-02-14
Accepted
2025-02-14 20:03:33
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 9772
  Complete submission text file 0001104659-25-014386.txt   11461
Mailing Address ONE LETTERMAN DRIVE BUILDING D, SUITE D3-300 SAN FRANCISCO CA 94129
Business Address ONE LETTERMAN DRIVE BUILDING D, SUITE D3-300 SAN FRANCISCO CA 94129 415-489-9980
Redmile Group, LLC (Filed by) CIK: 0001425738 (see all company filings)

EIN.: 208592298 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G

Mailing Address 72 HAMMERSMITH ROAD LONDON X0 W14 8TH
Business Address 72 HAMMERSMITH ROAD LONDON X0 W14 8TH 44-0-20-3457 6900
Silence Therapeutics plc (Subject) CIK: 0001479615 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0
Type: SCHEDULE 13G | Act: 34 | File No.: 005-92205 | Film No.: 25632105
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)